RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down

Repligen (RGEN) reported strong third-quarter 2025 results, with adjusted EPS of $0.46 and total revenues of $189 million, both surpassing analyst estimates and representing significant year-over-year growth. The company subsequently raised its 2025 revenue outlook to $729-$737 million. However, the stock declined 5.9% following the announcement, likely due to a tightened adjusted EPS guidance range of $1.65-$1.68, which saw the upper end slightly reduced from prior expectations, impacting investor sentiment despite the otherwise positive performance.

Analysis

Repligen (RGEN) delivered a strong third quarter for 2025, reporting adjusted EPS of $0.46, which surpassed the Zacks Consensus Estimate of $0.42, and total revenues of $189 million, exceeding the $181 million estimate. This represented a 22% year-over-year revenue increase, with organic revenue growth, excluding acquisitions and currency, reaching 18%, underpinned by over 20% growth in total orders and double-digit expansion across all franchises. Revenues from consumables, biopharma, and CDMO sales each grew by 20% year-over-year.

Despite this robust top-line performance and a raised 2025 revenue outlook to $729-$737 million (from $715-$735 million), RGEN shares declined 5.9% following the announcement. The negative market reaction was primarily attributed to a tightened adjusted EPS guidance range of $1.65-$1.68, down from the prior $1.65-$1.72, and a reduced adjusted operating income forecast, which collectively weighed on investor sentiment.

While adjusted gross margin improved by 260 basis points year-over-year to 53.3%, adjusted operating margin slightly decreased to 14.2% from 14.9% in the prior year, driven by significant increases in R&D (34.6%) and SG&A (32.7%) expenses. The company maintains a healthy cash position of $749 million as of September 30, 2025, but currently holds a Zacks Rank #4 (Sell).

Key Decisions for Investors

• Investors should closely monitor future guidance revisions, particularly for EPS, as the recent tightening negatively impacted market sentiment despite strong revenue performance.
• Evaluate the sustainability of Repligen's organic revenue growth against rising operating expenses to assess future profitability trends and potential margin pressures.
• Consider the implications of the Zacks Rank #4 (Sell) in conjunction with the mixed Q3 results and guidance when assessing RGEN's investment profile.